Yang Tsai-Hsiu, Hu Miao-Lin
Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Taiwan.
Nutr Cancer. 2006;55(2):224-31. doi: 10.1207/s15327914nc5502_14.
Cellular methylation imbalance is associated with tumor progression, hepatic cancer, and cardiovascular disease. S-Adenosylhomocysteine (SAH) is an inhibitor of cellular methyltransferases, and increasing evidence suggests that SAH rather than homocysteine (Hcy) plays a crucial role in mediating these disorders related to methylation imbalance. The anti-metastatic gene nm23-H1 was recently identified in murine and human cancer lines, and the expressions of nm23-H1 mRNA and protein have been shown to be useful tumor invasion markers. We investigated the relationships of tumor cell invasion activities with the intracellular levels of SAH and Hcy and the level of DNA methylation (measured as the cellular content of 5-methyldeoxycytidine, 5-mdc) in four hepatocarcinoma cell lines (Sk-Hep1, J5, Hep-G2, Hep-3B) and one normal liver cell line (Chang's liver cells) with different invasion activities (Sk-Hep1 > J5 > Hep-G2 = Hep-3B > Chang's liver cells). We found that the intracellular level of SAH was the highest in SK-Hep1 cells and was correlated with the invasion activities (r = 0.75, P = 0.008), whereas the level of intracellular Hcy was the highest in Chang's liver cells and was not significantly correlated with the invasion activities of these cell lines (r = 0.24, P = 0.38). The levels of 5-mdc increased with decreasing invasion activities of these cell lines (r = 0.82, P = 0.002), that is, the order of DNA hypomethylation in these cell lines was Sk-Hep1 > J5 > Hep-G2 = Hep-3B > Chang's liver cells, because the lower levels of 5-mdc% represent the higher DNA hypomethylation. Thus, our results demonstrate that SAH rather than Hcy is associated with invasion activities of hepatoma cells, and they suggest that SAH may play an important role in the invasion activities through DNA hypomethylation.
细胞甲基化失衡与肿瘤进展、肝癌及心血管疾病相关。S-腺苷同型半胱氨酸(SAH)是细胞甲基转移酶的抑制剂,越来越多的证据表明,在介导这些与甲基化失衡相关的疾病中,起关键作用的是SAH而非同型半胱氨酸(Hcy)。抗转移基因nm23-H1最近在小鼠和人类癌细胞系中被发现,nm23-H1 mRNA和蛋白的表达已被证明是有用的肿瘤侵袭标志物。我们研究了四种具有不同侵袭活性(Sk-Hep1 > J5 > Hep-G2 = Hep-3B > Chang肝细胞)的肝癌细胞系(Sk-Hep1、J5、Hep-G2、Hep-3B)和一种正常肝细胞系(Chang肝细胞)中肿瘤细胞侵袭活性与细胞内SAH和Hcy水平以及DNA甲基化水平(以5-甲基脱氧胞苷即5-mdc的细胞含量衡量)之间的关系。我们发现,SK-Hep1细胞中的细胞内SAH水平最高,且与侵袭活性相关(r = 0.75,P = 0.008),而Chang肝细胞中的细胞内Hcy水平最高,且与这些细胞系的侵袭活性无显著相关性(r = 0.24,P = 0.38)。5-mdc的水平随着这些细胞系侵袭活性的降低而升高(r = 0.82,P = 0.002),也就是说,这些细胞系中DNA低甲基化的顺序为Sk-Hep1 > J5 > Hep-G2 = Hep-3B > Chang肝细胞,因为较低的5-mdc%水平代表较高的DNA低甲基化。因此,我们的结果表明,与肝癌细胞侵袭活性相关的是SAH而非Hcy,并且提示SAH可能通过DNA低甲基化在侵袭活性中发挥重要作用。